Skip to main content
. 2016 Nov 24;7(52):86766–86780. doi: 10.18632/oncotarget.13575

Figure 3.

Figure 3

Panel A: qRT-PCR quantification and Western Blot analysis of SYK and LGALS1 after trabectedin (5 nM) treatment on MT-CHC01 cells. Panel B and C: qRT-PCR quantification and Western Blot analysis of SYK and LGALS1, respectively, after silencing. NT: not treated; OLIGO: cells treated with oligofectamine; siRNA CN: cells treated with negative control siRNA; siRNA1 and siRNA2: two different siRNA for SYK or LGALS; COMBO: combination of siRNA1 and siRNA2.